Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA048905-07
Application #
2093095
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1990-01-01
Project End
1996-12-31
Budget Start
1996-01-01
Budget End
1996-12-31
Support Year
7
Fiscal Year
1996
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Pharmacology
Type
Schools of Dentistry
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Pei, Z; Sebti, S M (1996) Cys102 and His398 are required for bleomycin-inactivating activity but not for hexamer formation of yeast bleomycin hydrolase. Biochemistry 35:10751-6
Pei, Z; Calmels, T P; Creutz, C E et al. (1995) Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells. Mol Pharmacol 48:676-81
Morris, G; Mistry, J S; Jani, J P et al. (1992) Neutralization of bleomycin hydrolase by an epitope-specific antibody. Mol Pharmacol 42:57-62
Jani, J P; Mistry, J S; Morris, G et al. (1992) In vivo circumvention of human colon carcinoma resistance to bleomycin. Cancer Res 52:2931-7
Jani, J P; Mistry, J S; Morris, G et al. (1992) In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64. Oncol Res 4:59-63
Mistry, J S; Jani, J P; Morris, G et al. (1992) Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b. Cancer Res 52:709-18
Sebti, S M; Jani, J P; Mistry, J S et al. (1991) Metabolic inactivation: a mechanism of human tumor resistance to bleomycin. Cancer Res 51:227-32
Morris, G; Mistry, J S; Jani, J P et al. (1991) Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells. Biochem Pharmacol 41:1559-66